Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,746.01
(
0.33%
)
News Focus
News Focus
Post# of 257265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WID post# 88920

Tuesday, 01/12/2010 11:43:05 PM

Tuesday, January 12, 2010 11:43:05 PM

Post# of 257265
Re: IDIX report from ‘New BioMedicine’

In February–March 2010, we expect Idenix Pharmaceuticals, Inc. (IDIX), to release the data from the Phase II trial of IDX184, designed for the treatment of hepatitis C virus (HCV) infection.

I think the IDX184 data release is more likely to occur at EASL in April:
http://www2.kenes.com/liver-congress/pages/home.aspx .

JMHO, FWIW


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today